Global Survey on the Impact of Decentralized Clinical Trials (DCTs) on Sponsor-CRO Collaborations
The Tufts Center for the Study of Drug Development at the Tufts University School of Medicine is conducting an ambitious global study to characterize and benchmark the impact of decentralized clinical trials (DCTs) on sponsor-CRO collaborations. This is one of the most comprehensive surveys of its kind among clinical research professionals and it will gather critical baselines to compare against future results. We are focused on gaining insights and perceptions on this topic across a wide range of organizations and appreciate your time on this research.
Please click on the link below to complete the survey: Take the Survey
The survey should take approximately 30 minutes of your time. Your responses will be strictly confidential and will only be reported in the aggregate; none of the study findings can be traced back to any individual or organization. A summary report of de-identified, aggregate results will be shared with 10 pharmaceutical companies and contract research organizations (CROs) that funded the study. In appreciation for completing the survey, we’ll send you a summary of the results. Thank you in advance for your participation in this important research effort!
Please complete the survey by March 25, 2022.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
